has cleared its Investigational New Drug (IND) application for BL-M17D1, an antibody-drug conjugate (ADC) with a novel linker and payload technology. The IND supports the initiation of a phase 1 ...

Harbour BioMed submits IND application for HBM9378/SKB378 to China NMPA to treat chronic obstructive pulmonary disease: Suzhou, China Monday, November 11, 2024, 17:00 Hrs [IST] Ha ...

submitted the company's Investigational New Drug (IND) application for CS231295 tablets, a Class 1 innovative drug for the treatment of tumors. The application has been accepted by the Center for ...

SystImmune, Inc (SystImmune), a clinical-stage biotechnology company, announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for BL-M17D1 ...

Tyra Biosciences (TYRA) announced that the FDA cleared its Investigational New Drug application for Tyra-300 allowing the company to proceed ...

SUZHOU, China, Oct. 17, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966 HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (stock code: 1093.HK) jointly announced that an application ...

Detailed price information for Aligos Therapeutics Inc (ALGS-Q) from The Globe and Mail including charting and trades.

Rensselaer Polytechnic Institute’s Christopher Cioffi, Ph.D., Thomas and Constance D'Ambra Professor in Organic Chemistry, ...

has lifted the clinical hold on the investigational new drug application for the Phase 1 clinical trial evaluating OCU200, a recombinant fusion protein consisting of tumstatin and transferrin, for ...

submitted the company's Investigational New Drug (IND) application for CS231295 tablets, a Class 1 innovative drug for the treatment of tumors. The application has been accepted by the Center for Drug ...

SUZHOU, China, Oct. 17, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966 HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (stock code: 1093.HK) jointly announced that an application ...